Pfizer’s In-Line Guidance Offers Relief to Weary Investors

(Bloomberg) -- Pfizer Inc. forecast 2025 sales and earnings in line with analysts’ projections, a step toward fending off an activist investor’s claims that the drugmaker is being mismanaged.Most Read from BloombergHong Kong's Expat Party Hub Reshaped by Chinese InfluxHow California Sees the World, and ItselfLondon’s Tube Fares Are Set to Rise by 4.6% Next YearRevenue next year will be $61 billion to $64 billion, Pfizer said Tuesday in a statement, while Wall Street analysts surveyed by Bloomber